ArticleCureus2025
Assessment of Serum Phosphate Levels in Chronic Kidney Disease Patients Across Different Stages of Kidney Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Role of Inositol Hexakisphosphate Kinases in Vascular Smooth Muscle Cell Calcification.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to determine the serum phosphate level in patients diagnosed with chronic kidney disease (CKD) across different stages of the disease in a tertiary care hospital in Peshawar. MATERIALS AND
methodsThis cross-sectional study was conducted in the Nephrology Department at Lady Reading Hospital, Peshawar, from August 2024 to January 2025. Over a six-month period, participants were recruited using a non-probability convenience sampling technique. The sample size of 296 was calculated using the WHO sample size calculator, with a 5% margin of error. The study included patients aged 18 years and older, of both sexes, diagnosed with any stage of CKD. Patients with acute kidney injury or significant disorders affecting phosphorus metabolism (e.g., primary hyperparathyroidism or malignancies) were excluded.
resultsA total of 296 patients with CKD from various etiologies were included in this study, consisting of 124 males (41.9%) and 172 females (58.1%). The age distribution was as follows: 20-39 years (17.6%), 40-49 years (26.7%), 50-59 years (29.4%), and ≥60 years (26.4%), with a mean age of 50.26 ± 12.14 years. Among the participants, 12.8% had CKD stage 2, 23% had stage 3, 33.4% had stage 4, and 30.7% had stage 5. Of the 296 patients, 77 (26%) were receiving hemodialysis, while 219 (74%) were on conservative management. The overall incidence of hyperphosphatemia was 56% (166 participants). Stage-wise, hyperphosphatemia was observed in 31.5% of CKD stage 2, 38.2% of stage 3, 72.7% of stage 4, and 61.5% of stage 5 patients.
conclusionThe study has shown a higher burden of hyperphosphatemia among CKD patients, with an overall incidence of 56%. The prevalence of hyperphosphatemia increased with advancing CKD stages, peaking at CKD stage 4 (72.7%) and continuously remaining high in stage 5 (61.5%). These results stressed the need for early detection and effective management of hyperphosphatemia, particularly in the later stages of CKD, to lessen its associated complications. Moreover, the demographic distribution, with a mean age of 50.26 ± 12.14 years and a female predominance (58.1%), reflects the need for targeted interventions tailored to this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.